We further confirmed the direct association of CFR detected by IHC with outcomes following anti-PD-1/PD-L1 immunotherapy in a retrospective and independent cohort of 61 patients with advanced NSCLC in FCHC. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.